Abbott Laboratories

Abbott Laboratories Beats on EPS, Stock Up 4.24%

Abbott Laboratories reported a better-than-expected EPS for Q2 2023, which contributed to a positive stock reaction, with shares rising by 4.24%. However, there was no revenue figure provided, leaving some uncertainty about overall performance. The lack of guidance and management commentary means investors will need to wait for further information to assess future prospects.